Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae) By Skin Irritation Assessments,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
1,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae) By Vital Signs Measurements,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
2,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae) By Ecg Assessment,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
3,NCT04984707,Androgenetic Alopecia,Incidence Of Treatment-Emergent Adverse Events (Teae) By Clinical Lab Tests,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
4,NCT04984707,Androgenetic Alopecia,Incidence Of Study Drug Related Teaes,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
5,NCT04984707,Androgenetic Alopecia,"Auc From Time 0 And Extrapolated To Infinite Time, Total Exposure(Aucinf)",Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
6,NCT04984707,Androgenetic Alopecia,Auc From Time 0 To The Last Non-Zero Concentration(Auclast),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
7,NCT04984707,Androgenetic Alopecia,Maximum Observed Concentration (Cmax),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
8,NCT04984707,Androgenetic Alopecia,Time At Which Cmax Was First Observed(Tmax),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
9,NCT04984707,Androgenetic Alopecia,Half Life（T½）,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
10,NCT04984707,Androgenetic Alopecia,"Apparent Total Systemic Clearance, Calculated As Dose/Aucinf(Cl/F)",Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
11,NCT04984707,Androgenetic Alopecia,Apparent Volume Of Distribution(Vd/F),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
12,NCT04984707,Androgenetic Alopecia,Elimination Rate Constant（Kel）,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
13,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Global Cognition,Not Mentioned,Not Mentioned,At Baseline.,Primary Endpoint
14,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Global Cognition,Not Mentioned,Not Mentioned,Immediately After Intervention.,Primary Endpoint
15,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Global Cognition,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Primary Endpoint
16,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Global Cognition,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Primary Endpoint
17,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Global Cognition,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Primary Endpoint
18,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Memory,Not Mentioned,Not Mentioned,At Baseline.,Primary Endpoint
19,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Memory,Not Mentioned,Not Mentioned,Immediately After Intervention.,Primary Endpoint
20,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Memory,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Primary Endpoint
21,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Memory,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Primary Endpoint
22,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Memory,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Primary Endpoint
23,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Attention,Not Mentioned,Not Mentioned,At Baseline.,Primary Endpoint
24,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Attention,Not Mentioned,Not Mentioned,Immediately After Intervention.,Primary Endpoint
25,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Attention,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Primary Endpoint
26,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Attention,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Primary Endpoint
27,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Attention,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Primary Endpoint
28,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Visual/Spatial Function,Not Mentioned,Not Mentioned,At Baseline.,Primary Endpoint
29,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Visual/Spatial Function,Not Mentioned,Not Mentioned,Immediately After Intervention.,Primary Endpoint
30,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Visual/Spatial Function,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Primary Endpoint
31,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Visual/Spatial Function,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Primary Endpoint
32,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Visual/Spatial Function,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Primary Endpoint
33,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Executive Function,Not Mentioned,Not Mentioned,At Baseline.,Primary Endpoint
34,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Executive Function,Not Mentioned,Not Mentioned,Immediately After Intervention.,Primary Endpoint
35,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Executive Function,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Primary Endpoint
36,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Executive Function,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Primary Endpoint
37,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Cognition-Executive Function,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Primary Endpoint
38,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Iadl,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
39,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Iadl,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
40,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Iadl,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
41,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Iadl,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
42,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Iadl,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
43,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
44,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
45,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
46,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
47,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Senior Fitness Test (Sft),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
48,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Unipedal Stance Test (Ust),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
49,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Unipedal Stance Test (Ust),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
50,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Unipedal Stance Test (Ust),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
51,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Unipedal Stance Test (Ust),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
52,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Physical Function-Unipedal Stance Test (Ust),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
53,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Global Well-Being Scale (Gwbs),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
54,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Global Well-Being Scale (Gwbs),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
55,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Global Well-Being Scale (Gwbs),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
56,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Global Well-Being Scale (Gwbs),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
57,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Global Well-Being Scale (Gwbs),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
58,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
59,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
60,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
61,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
62,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
63,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
64,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
65,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
66,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
67,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
68,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
69,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
70,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
71,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
72,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Utility,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
73,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
74,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
75,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
76,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
77,NCT04984694,Cognitive Dysfunction|Cognitive Change|Independent Living|Quality Of Life|Video Games,Quality Of Life-Eq5D-Visual Analogue Scale,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
78,NCT04984564,Educational Problems,Feedback Of Individual Fellow In Training On Virtual And Simulator Based Learning.,Not Mentioned,Not Mentioned,Survey Was Conducted From August To July 2020. Subjects Had Two Month Period To Respond.,Primary Endpoint
79,NCT04984564,Educational Problems,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
80,NCT04984135,Coronary Stenosis|Drug-Coated Balloon,In-Segment Late Lumen Loss,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
81,NCT04984135,Coronary Stenosis|Drug-Coated Balloon,Target Lesion Failure,Not Mentioned,Not Mentioned,6 Months,Secondary Endpoint
82,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs","Mmp8, Mmp9",Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
83,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs","Il1, Il6,Il8,Il17",Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
84,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Tnf Alfa,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
85,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Rank-L,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
86,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Opg,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
87,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Cal,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
88,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Ppd,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
89,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Gi,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
90,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Fmps,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
91,NCT04983849,"Mmp8, Mmp9|Il1, Il6, Il8, Il17|Tnf Alfa|Rank-L|Opg|Cal|Ppd|Gi|Fmps|Fmbs",Fmbs,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
92,NCT04983719,Atypical|Myoma,Evaluation Of Video,Not Mentioned,Not Mentioned,Day 1,Primary Endpoint
93,NCT04983719,Atypical|Myoma,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
94,NCT04983641,Orthopedic Disorder,"Pre-Visit Promis Completion Rates In Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
95,NCT04983641,Orthopedic Disorder,"At-Visit Promis Completion Rates In Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
96,NCT04983641,Orthopedic Disorder,"Overall (Pre-Visit And At-Visit) Promis Completion Rates In Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
97,NCT04983641,Orthopedic Disorder,Time To Pre-Visit Promis Form Completion,Not Mentioned,Not Mentioned,1 Week,Secondary Endpoint
98,NCT04983641,Orthopedic Disorder,Promis Form Completion Rates According To Patient Demographics,Not Mentioned,Not Mentioned,1 Week,Secondary Endpoint
99,NCT04983524,"Post-Operative Pain, Chronic|Necrotic Pulp",Post-Operative Pain,Not Mentioned,Not Mentioned,One Week. Line Of 10 Points,Primary Endpoint
100,NCT04983524,"Post-Operative Pain, Chronic|Necrotic Pulp",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
101,NCT04983459,Prostatic Neoplasms|Recurrence,Detection Rate Per Patient Of Pet-Psma For The Detection Of Biochemical Recurrence.,Not Mentioned,Not Mentioned,12 Months,Primary Endpoint
102,NCT04983459,Prostatic Neoplasms|Recurrence,Detection Rate Per Region Of Psma-Pet For The Detection Of Biochemical Recurrence,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
103,NCT04983381,Pelvic Pain|Pelvic Floor; Relaxation,Pelvic Examination Of Anxiety,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
104,NCT04983381,Pelvic Pain|Pelvic Floor; Relaxation,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
105,NCT04983212,Peri-Implantitis,Prevalence Of Peri-Implantitis,Not Mentioned,Not Mentioned,01/01/2015 - 01/01/2020,Primary Endpoint
106,NCT04983212,Peri-Implantitis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
107,NCT04983160,Chronic Kidney Disease,Circulating Endothelial Progenitor Cells Concentration And Microparticles Derived From Endothelial Cells,Not Mentioned,Not Mentioned,"Data Collected After 4 Weeks, 8 Weeks And 12 Weeks.",Primary Endpoint
108,NCT04983160,Chronic Kidney Disease,Level Of Oxidative Stress,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
109,NCT04983160,Chronic Kidney Disease,Level Of Micro Inflammation,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
110,NCT04983160,Chronic Kidney Disease,Level Of Endothelial Dysfunction,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
111,NCT04983160,Chronic Kidney Disease,Blood Pressure,Not Mentioned,Not Mentioned,"Each Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks) For 24 Hours",Secondary Endpoint
112,NCT04983160,Chronic Kidney Disease,Glomerular Filtration Ratio,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks)",Secondary Endpoint
113,NCT04983160,Chronic Kidney Disease,Microalbuminuria / Proteinuria,Not Mentioned,Not Mentioned,"Daily, Using First Urine Of The Day As A Sample.",Secondary Endpoint
114,NCT04983147,Obesity,Introductory Information Form (Questionnaire),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
115,NCT04983147,Obesity,Health Belief Model Scale In Obesity (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
116,NCT04983147,Obesity,Health Belief Model Scale In Obesity-Importance Of Health (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
117,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Sensitivity (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
118,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Severity (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
119,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Benefit (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
120,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Barrier (Questionnaire-Scale),Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
121,NCT04983147,Obesity,Height Meter,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
122,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
123,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
124,NCT04983147,Obesity,Health Belief Model Scale In Obesity ((Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
125,NCT04983147,Obesity,Health Belief Model Scale In Obesity-Importance Of Health (Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
126,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Sensitivity (Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
127,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Severity (Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
128,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Benefit (Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
129,NCT04983147,Obesity,Health Belief Model Scale In Obesity- Perceived Barrier (Questionnaire-Scale),Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
130,NCT04983147,Obesity,Height Meter,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
131,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
132,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
133,NCT04983056,Fournier Gangrene,Number Of Patients Who Died For Fournier Gangrene,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
134,NCT04983056,Fournier Gangrene,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
135,NCT04982978,Vaping Related Disorder,Effect Of Threat Appraisal On Vaping Intention,Not Mentioned,Not Mentioned,6-Weeks,Primary Endpoint
136,NCT04982978,Vaping Related Disorder,Effect Of Perceived Vulnerability On Intention,Not Mentioned,Not Mentioned,6-Weeks,Secondary Endpoint
137,NCT04982978,Vaping Related Disorder,Effect Of Perceived Severity On Intention,Not Mentioned,Not Mentioned,6-Weeks,Secondary Endpoint
138,NCT04982874,Drug Use,Geometric Mean Ratio,Not Mentioned,Not Mentioned,1 Month,Primary Endpoint
139,NCT04982874,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,1 Month,Primary Endpoint
140,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
141,NCT04982874,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
142,NCT04982861,Drug Use,Geometric Mean Ratio,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
143,NCT04982861,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
144,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
145,NCT04982861,Drug Use,Pharmacokinetics Parameter,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
146,NCT04982809,Interstitial Lung Disease,Krebs Von Den Lungen - 6 (Kl-6),Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
147,NCT04982809,Interstitial Lung Disease,Respiratory Function Assessment; Fev1,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
148,NCT04982809,Interstitial Lung Disease,Respiratory Function Assessment; Fvc,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
149,NCT04982809,Interstitial Lung Disease,Respiratory Function Assessment; Fev/Fvc Ratio,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
150,NCT04982809,Interstitial Lung Disease,Respiratory Function Assessment; 6Mwd,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
151,NCT04982809,Interstitial Lung Disease,Respiratory Function Assessment; % O2 Desaturation,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
152,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Visual Analog Scale(Vas),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
153,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Neck Pain And Disability Scale (Npds),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
154,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Neck And Jaw Range Of Motion (Rom),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
155,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Pittsburg Sleep Quality Index (Puqi),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
156,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Beck Depression Inventory (Bdi),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
157,NCT04982601,Temporomandibular Disorders|Myofascial Pain Dysfunction Syndrome|Temporomandibular Joint Pain|Range Of Motion|Yoga|Quality Of Life,Short Form 36 (Sf36),Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
158,NCT04982523,Post Traumatic Stress Disorder,Change Of Post-Traumatic Stress Symptoms,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Primary Endpoint
159,NCT04982523,Post Traumatic Stress Disorder,Change Of Depression,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
160,NCT04982523,Post Traumatic Stress Disorder,Fuctional Health,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
161,NCT04982523,Post Traumatic Stress Disorder,College To Adaptation,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
162,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Reading Speed Day 0,Not Mentioned,Not Mentioned,Day 0,Primary Endpoint
163,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Reading Speed M3,Not Mentioned,Not Mentioned,Month 3,Primary Endpoint
164,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Visual Acuity Using The Etdrs Chart Day 0,Not Mentioned,Not Mentioned,Day 0,Secondary Endpoint
165,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Visual Acuity Using The Etdrs Chartm3,Not Mentioned,Not Mentioned,Month 3,Secondary Endpoint
166,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Maculare Thickness Day0,Not Mentioned,Not Mentioned,Day 0,Secondary Endpoint
167,NCT04982484,Ophthalmopathy|Wet Macular Degeneration,Maculare Thickness M3,Not Mentioned,Not Mentioned,Month 3,Secondary Endpoint
168,NCT04982341,Hypoxemic Respiratory Failure,Number Of Patients Without Intubation,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 28 Days",Primary Endpoint
169,NCT04982341,Hypoxemic Respiratory Failure,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
170,NCT04982263,Covid19,Correlation Of Disease Severity With Results Of Laboratory Test,Not Mentioned,Not Mentioned,Baseline Results Of Coagulation Profile And Baseline Disease Severity Assessment,Primary Endpoint
171,NCT04982263,Covid19,Agreement Of Abnormalities In Coagulation Profile With Measured Inflammatory Markers,Not Mentioned,Not Mentioned,Baseline Measurement Of Inflammatory Markers,Secondary Endpoint
172,NCT04982159,Invasive Fusariosis,Clinical Evolution,Not Mentioned,Not Mentioned,6 Weeks After Diagnosis,Primary Endpoint
173,NCT04982159,Invasive Fusariosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
174,NCT04982055,Critical Illness,Peak Anti-Xa Activity,Not Mentioned,Not Mentioned,Peak Anti-Xa Activity Obtained 4 Hours After Start Of Low Molecular Weight Heparin Administration,Primary Endpoint
175,NCT04982055,Critical Illness,Trough Anti-Xa Activity,Not Mentioned,Not Mentioned,Trough Anti-Xa Activity Measured 24 Hours After Start Of Low Molecular Weight Administration,Secondary Endpoint
176,NCT04982055,Critical Illness,Auc (0-24H),Not Mentioned,Not Mentioned,0-24 Hours,Secondary Endpoint
177,NCT04981652,Dairy Products|Muscle Protein Synthesis|Aging|Physical Activity,Muscle Protein Synthesis,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Primary Endpoint
178,NCT04981652,Dairy Products|Muscle Protein Synthesis|Aging|Physical Activity,Western Blotting,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Secondary Endpoint
179,NCT04981561,Major Depressive Disorder,Treatment Emergent Adverse Events,Not Mentioned,Not Mentioned,28 Days,Primary Endpoint
180,NCT04981561,Major Depressive Disorder,"Pharmacokinetics, Maximum Plasma Concentration",Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
181,NCT04981561,Major Depressive Disorder,"Pharmacokinetics, Time To Maximum Plasma Concentration",Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
182,NCT04981561,Major Depressive Disorder,"Pharmacokinetics, Area Under The Curve For Plasma Concentration",Not Mentioned,Not Mentioned,72 Hours,Secondary Endpoint
183,NCT04981483,Placenta Accreta,Incidence Rate Of Conserving Woman'S Uterus,Not Mentioned,Not Mentioned,Intraoperative,Primary Endpoint
184,NCT04981483,Placenta Accreta,"Number Of Units Of Packed Red Blood Cells , Fresh Frozen Plasma Transfused ,Postoperative Haemoglobin",Not Mentioned,Not Mentioned,Till 48 Hours Postpartum,Secondary Endpoint
185,NCT04981483,Placenta Accreta,Incidence Rate Of Cesarean Hysterectomy Needed,Not Mentioned,Not Mentioned,Intraoperative And 48 Hours Postpartum,Secondary Endpoint
186,NCT04981483,Placenta Accreta,Incidence Of Puerperal Sepsis,Not Mentioned,Not Mentioned,Till 6 Weeks Postpartum,Secondary Endpoint
187,NCT04981379,Covid19,Worsening Of Clinical Findings,Not Mentioned,Not Mentioned,During The Study,Primary Endpoint
188,NCT04981379,Covid19,Complete Resolution Of Symptoms And Signs,Not Mentioned,Not Mentioned,Fifth Day After Examination,Secondary Endpoint
189,NCT04981379,Covid19,Complete Resolution Of Symptoms And Signs,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
190,NCT04981379,Covid19,Negative Rt-Pcr Test For Sars-Cov-2,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
191,NCT04981379,Covid19,"Determination Of Igm, Igg Levels For Sars-Cov-2",Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
192,NCT04981379,Covid19,Negative Rt-Pcr Test For Sars-Cov-2,Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
193,NCT04981379,Covid19,"Determination Of Igm, Igg Antibodies",Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
194,NCT04981379,Covid19,Development Of Signs Of Pneumonia,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
195,NCT04981379,Covid19,Requirement Of Respiratory Support With Oxygen Mask,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
196,NCT04981379,Covid19,Requirement Of Respiratory Support With High Flow Oxygen,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
197,NCT04981379,Covid19,Requirement Of Mechanical Ventilation,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
198,NCT04981379,Covid19,Death,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
199,NCT04981379,Covid19,The Rate Of Discontinuation Of Treatments Due To Side Effects,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
200,NCT04981379,Covid19,Time To Improvement Of Symptoms After The Initiation Of Study Drugs,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
201,NCT04981249,Covid-19|Chronic Disease,Covid-19 Severe Infection,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
202,NCT04981249,Covid-19|Chronic Disease,Covid-19 Mortality,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
203,NCT04981249,Covid-19|Chronic Disease,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
204,NCT04981197,Heart Failure,Changes In The Modified Piper Fatigue Scale Scores,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
205,NCT04981197,Heart Failure,Changes In The Minnesota Living With Heart Failure Questionnaire Scores,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
206,NCT04981197,Heart Failure,Changes In The Pittsburgh Sleep Quality Index Scores,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
207,NCT04981197,Heart Failure,Changes In The Hospital Anxiety And Depression Scale Scores,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
208,NCT04981197,Heart Failure,Changes In Heart Rate Variability,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
209,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 58.2; Control 54.1),Primary Endpoint
210,NCT04981106,Exercise,Womac Osteoarthritis Index,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 89.3; Control 88.1),Primary Endpoint
211,NCT04981106,Exercise,Beck'S Depression Inventory,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 21.6; Control 22.1),Primary Endpoint
212,NCT04981106,Exercise,Tampa Kinesiophobia Index,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 36.9; Control 42.9),Secondary Endpoint
213,NCT04981106,Exercise,Womac Osteoarthritis Index,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 29; Control 70.5),Secondary Endpoint
214,NCT04981106,Exercise,Beck'S Depression Inventory,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 6.9; Control 13.2),Secondary Endpoint
215,NCT04981080,Detrusor Underactivity|Bladder Outlet Obstruction,Detrusor Underactivity,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
216,NCT04981080,Detrusor Underactivity|Bladder Outlet Obstruction,Bladder Outlet Obstruction,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
217,NCT04981080,Detrusor Underactivity|Bladder Outlet Obstruction,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
218,NCT04981054,"Bladder Oversensitivity|Detrusor, Overactive",Bladder Oversensitivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
219,NCT04981054,"Bladder Oversensitivity|Detrusor, Overactive",Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
220,NCT04981054,"Bladder Oversensitivity|Detrusor, Overactive",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
221,NCT04981015,Bladder Oversensitivity,Correlation Between Parameters,Not Mentioned,Not Mentioned,July 2009 To December 2020,Primary Endpoint
222,NCT04981015,Bladder Oversensitivity,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
223,NCT04980989,"Breast Cancer, Early-Onset",Patient Preference For Follow-Up Modality,Not Mentioned,Not Mentioned,At 12 Months During Follow-Up Of Early Breast Cancer,Primary Endpoint
224,NCT04980989,"Breast Cancer, Early-Onset",Quality Of Life During Follow-Up Modality,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
225,NCT04980989,"Breast Cancer, Early-Onset",Patient Satisfaction,Not Mentioned,Not Mentioned,At 6 Months And 12 Months,Secondary Endpoint
226,NCT04980989,"Breast Cancer, Early-Onset",Symptoms,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
227,NCT04980989,"Breast Cancer, Early-Onset",Use Of Other Healthcare Services,Not Mentioned,Not Mentioned,At 6 Months And 12 Months,Secondary Endpoint
228,NCT04980937,Traumatic Injury|Peroneal Nerve Injury|Sport Injury,Successful Nerve Reconstruction,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
229,NCT04980937,Traumatic Injury|Peroneal Nerve Injury|Sport Injury,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
230,NCT04980729,Pelvic Tumor,Compare The Change Of Acetabular Rotation Center Before And After Surgery Between The Template-Guided Group And The Traditional Operation Group.,Not Mentioned,Not Mentioned,"""Through Study Completion, An Average Of 2 Years""",Primary Endpoint
231,NCT04980729,Pelvic Tumor,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
232,NCT04980586,"Obstructive Sleep Apnea|Breathing, Sleep-Disordered|Muscle Weakness|Muscle Disorder|Face|Swallowing Disorder",Cheeks Appearance,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Primary Endpoint
233,NCT04980586,"Obstructive Sleep Apnea|Breathing, Sleep-Disordered|Muscle Weakness|Muscle Disorder|Face|Swallowing Disorder",Thickness Evaluation Of Specific Orofacial Muscles,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Secondary Endpoint
234,NCT04980586,"Obstructive Sleep Apnea|Breathing, Sleep-Disordered|Muscle Weakness|Muscle Disorder|Face|Swallowing Disorder",Tongue And Cheeks Pressure,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Secondary Endpoint
235,NCT04980508,Erectile Dysfunction Due To Diseases Classified Elsewhere|Covid19,Corpus Cavernosum Electromyography Amplitudes And Frequency,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
236,NCT04980508,Erectile Dysfunction Due To Diseases Classified Elsewhere|Covid19,Corpus Cavernosum Electromyography Relaxation Degree,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
237,NCT04980508,Erectile Dysfunction Due To Diseases Classified Elsewhere|Covid19,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
238,NCT04980274,Critically Ill Patients,Improvement In Sofa Score After 48 Hours Of Icu Stay,Not Mentioned,Not Mentioned,48 Hours,Primary Endpoint
239,NCT04980274,Critically Ill Patients,28 Day Mortality,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
240,NCT04980274,Critically Ill Patients,Length Of Time Without Mechanical Ventilation,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
241,NCT04980274,Critically Ill Patients,Length Of Time Without Vasopressor,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
242,NCT04980209,Femoroacetabular Impingement,Vas Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
243,NCT04980209,Femoroacetabular Impingement,Mhhs Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
244,NCT04980209,Femoroacetabular Impingement,Hip Ct,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
245,NCT04980209,Femoroacetabular Impingement,Hip X-Ray,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
246,NCT04980209,Femoroacetabular Impingement,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
247,NCT04980196,Urogenital Prolapse,Urological Outcome Following Surgery In Women With Pelvic Organ Prolapse And Urinary Tract Dysfunction.,Not Mentioned,Not Mentioned,3Months,Primary Endpoint
248,NCT04980196,Urogenital Prolapse,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
249,NCT04980131,Vertebral Fracture,"First Puncture Success Rate,Number Of Insertions Before Reaching The Desired Position, Number Of Fluoroscopy Before Reaching The Desired Position, Radiation Dosage Before Reaching The Desired Position, Operation Time Before Reaching The Desired Position",Not Mentioned,Not Mentioned,Twenty Months,Primary Endpoint
250,NCT04980131,Vertebral Fracture,Vas Scores After Surgery,Not Mentioned,Not Mentioned,Twenty-Two Months,Primary Endpoint
251,NCT04980131,Vertebral Fracture,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
252,NCT04980118,Breast Cancer|Body Weight Changes|Weight Loss|Nutrition Related Cancer,To Evaluate A Nutritional Intervention For Women Newly Diagnosed With Breast Cancer 9 Weight Control And Physical Activity Program.,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
253,NCT04980118,Breast Cancer|Body Weight Changes|Weight Loss|Nutrition Related Cancer,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
254,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Serious Adverse Events (Saes),Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
255,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Serious Adverse Drug Reactions (Adrs),Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
256,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Unexpected Adverse Events,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
257,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Unexpected Adverse Drug Reactions (Adrs),Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
258,NCT04980040,Type 2 Diabetes Mellitus,Haemoglobin (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
259,NCT04980040,Type 2 Diabetes Mellitus,Fasting Blood Glucose Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
260,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Hba1C < 7.00%,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
261,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants With Overall Improvement And Final Effectiveness Assessment,Not Mentioned,Not Mentioned,Up To Week 26,Secondary Endpoint
262,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Serious Adverse Events (Saes) And Serious Adverse Drug Reactions (Sadrs),Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
263,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Unexpected Adverse Events (Aes) And Adverse Drug Reactions (Adrs) Not Mentioned In Precautions,Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
264,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Expected/Already Known Adrs At Week 13,Not Mentioned,Not Mentioned,Week 13,Primary Endpoint
265,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Expected/Already Known Adrs At Week 26,Not Mentioned,Not Mentioned,Week 26,Primary Endpoint
266,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Expected/Already Known Adrs At Week 39,Not Mentioned,Not Mentioned,Week 39,Primary Endpoint
267,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Expected/Already Known Adrs At Week 52,Not Mentioned,Not Mentioned,Week 52,Primary Endpoint
268,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Expected/Already Known Adrs At Week 153,Not Mentioned,Not Mentioned,Week 153,Primary Endpoint
269,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Non-Serious Adrs,Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
270,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Abnormal Laboratory Findings Reported As Aes,Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
271,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Haemoglobin A1C (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
272,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Fasting Serum Glucose,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
273,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Total Cholesterol,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
274,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Low Density Lipoprotein-Cholesterol (Ldl-C),Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
275,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In High Density Lipoprotein-Cholesterol (Hdl-C),Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
276,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Body Weight,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
277,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Systolic Blood Pressure,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
278,NCT04980014,Type 2 Diabetes Mellitus,Change From Baseline In Diastolic Blood Pressure,Not Mentioned,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
279,NCT04979936,"Acute Cholecystitis|Empyema, Gallbladder","Operative Difficulties As Conversion, Operative Time, Biliary Injury",Not Mentioned,Not Mentioned,At The Time Of Cholecysctomy,Primary Endpoint
280,NCT04979936,"Acute Cholecystitis|Empyema, Gallbladder",Postoperative Complications,Not Mentioned,Not Mentioned,30 Days After The Operation,Primary Endpoint
281,NCT04979936,"Acute Cholecystitis|Empyema, Gallbladder",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
282,NCT04979689,Erbs Palsy,Modified Mallet Scale,Not Mentioned,Not Mentioned,12Th Weeks,Primary Endpoint
283,NCT04979689,Erbs Palsy,Goniometer,Not Mentioned,Not Mentioned,"12Th Weeks, 5Th Day",Secondary Endpoint
284,NCT04979481,Mental Health Wellness 1,Health,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
285,NCT04979481,Mental Health Wellness 1,Resilience,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
286,NCT04979481,Mental Health Wellness 1,Positive Coping,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
287,NCT04979481,Mental Health Wellness 1,Self-Esteem,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
288,NCT04979481,Mental Health Wellness 1,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
289,NCT04979364,Chronic Pain|Opioid Misuse,Psychometric Properties Of Pomi Scale,Not Mentioned,Not Mentioned,Once. At Inclusion (Test Phase),Primary Endpoint
290,NCT04979364,Chronic Pain|Opioid Misuse,Psychometric Properties Of Pomi Scale,Not Mentioned,Not Mentioned,Once. At 2 To 4 Weeks (Re-Test Phase),Primary Endpoint
291,NCT04979364,Chronic Pain|Opioid Misuse,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
292,NCT04979208,Coronavirus Disease 2019|Stroke|Acute Myocardial Infarction,Delay For Ami Patient,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
293,NCT04979208,Coronavirus Disease 2019|Stroke|Acute Myocardial Infarction,Delay For Stroke Patient,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
294,NCT04979208,Coronavirus Disease 2019|Stroke|Acute Myocardial Infarction,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
295,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Patient Survival,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
296,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Kidney Survival,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
297,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
298,NCT04979091,Covid19|Critical Illness,Sex Hormone In Critical Ill Covid-19 Patients,Not Mentioned,Not Mentioned,Day At Admission,Primary Endpoint
299,NCT04979091,Covid19|Critical Illness,Sex Hormone In Critical Ill Patients,Not Mentioned,Not Mentioned,Day At Admission,Primary Endpoint
300,NCT04979091,Covid19|Critical Illness,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
301,NCT04979026,Deep Venous Thrombosis,Change Of Peak Flow Velocity,Not Mentioned,Not Mentioned,"The Peak Flow Velocity Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
302,NCT04979026,Deep Venous Thrombosis,Change Of Flow Volume,Not Mentioned,Not Mentioned,"The Flow Volume Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
303,NCT04979026,Deep Venous Thrombosis,Number Of Participants With Stasis,Not Mentioned,Not Mentioned,"Stasis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
304,NCT04979026,Deep Venous Thrombosis,Number Of Participants With Deep Venous Thrombosis,Not Mentioned,Not Mentioned,"Deep Venous Thrombosis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
305,NCT04979026,Deep Venous Thrombosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
306,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,"Urinary Arachidonic Acid (Aa) Metabolites 2,3-Dinor-Thromboxane B2 (Txm) And Leukotriene E4 (Lte4)",Not Mentioned,Not Mentioned,14 Days,Primary Endpoint
307,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Urinary Aa Metabolites Txm And Lte4,Not Mentioned,Not Mentioned,7 Days,Secondary Endpoint
308,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Additional Aa Metabolites,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
309,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Exposure In Urine: Nicotine Equivalents And Cema,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
310,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Exposure In Urine: Tsnas,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
311,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Exposure In Blood: Carboxyhemoglobin,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
312,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Exposure In Blood: Nicotine And Cotinine,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
313,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Potential Harm: Feno,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
314,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Biomarkers Of Potential Harm: Abg,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
315,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Nasal Mucociliary Clearance (Nmc) Saccharin Transit Time (Stt),Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
316,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,T- And B-Lymphocytes And Natural Killer (Nk) Cell Profiles,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
317,NCT04979013,Smoking|Smoking Cessation|Tobacco Use,Changes In Platelet Aggregation,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
318,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program As Assessed Using Perceived Stress Scale,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
319,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program As Assessed Using Health-Related Quality Of Life,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
320,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program As Assessed Using Coping Strategies Questionnaire,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
321,NCT04978974,"Chronic Conditions, Multiple",Effects Of Stress Management Program As Assessed Using Baseline,Not Mentioned,Not Mentioned,Base Line Were Used In 5Th (Two Weeks And 3 Days) And 10Th Session (One Month And One Week From First Assessment),Secondary Endpoint
322,NCT04978961,Chronic Pain,Self-Reported Physical Disability,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Primary Endpoint
323,NCT04978961,Chronic Pain,Self-Reported Physical Disability,Not Mentioned,Not Mentioned,6-Month Follow-Up,Primary Endpoint
324,NCT04978961,Chronic Pain,Feasibility Of Intervention And Study (Attrition And Satisfaction Ratings),Not Mentioned,Not Mentioned,6-Month Follow-Up,Primary Endpoint
325,NCT04978961,Chronic Pain,Acceptability Of The Fact Intervention,Not Mentioned,Not Mentioned,6-Month Follow-Up,Primary Endpoint
326,NCT04978961,Chronic Pain,Chronic Pain Acceptance,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
327,NCT04978961,Chronic Pain,Chronic Pain Acceptance,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
328,NCT04978961,Chronic Pain,Engagement In Valued Activities,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
329,NCT04978961,Chronic Pain,Engagement In Valued Activities,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
330,NCT04978883,Sjogren'S Syndrome,"Observational Study, Data Analysis To Identify The Risk Factors Of Pss-Ild",Not Mentioned,Not Mentioned,6 Months From Baseline,Primary Endpoint
331,NCT04978883,Sjogren'S Syndrome,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
332,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,1. Week,Primary Endpoint
333,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,4. Week,Primary Endpoint
334,NCT04978805,Cancer,Visual Analog Scale,Not Mentioned,Not Mentioned,8. Week,Primary Endpoint
335,NCT04978805,Cancer,Pittsburgh Sleep Quality Index (Psqi),Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
336,NCT04978805,Cancer,Pittsburgh Sleep Quality Index (Psqi),Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
337,NCT04978805,Cancer,Pittsburgh Sleep Quality Index (Psqi),Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
338,NCT04978805,Cancer,Modified Medical Research Council (Mmrc),Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
339,NCT04978805,Cancer,Modified Medical Research Council (Mmrc),Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
340,NCT04978805,Cancer,Modified Medical Research Council (Mmrc),Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
341,NCT04978805,Cancer,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
342,NCT04978714,Urodynamic Stress Incontinence|Detrusor Overactivity,Urodynamic Stress Incontinence,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
343,NCT04978714,Urodynamic Stress Incontinence|Detrusor Overactivity,Detrusor Overactivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
344,NCT04978714,Urodynamic Stress Incontinence|Detrusor Overactivity,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
345,NCT04978688,Healthy,"Pk: Area Under The Concentration-Time Curve From Time Zero To Hour 24 (Auc0-24) Of Relugolix, E2, Estrone (El), Ethinylestradiol (Ee), Neta",Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
346,NCT04978688,Healthy,"Pk: Maximum Concentration (Cmax) Of Relugolix, E2, El, Neta",Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
347,NCT04978688,Healthy,"Pk: Time To Maximum Concentration (Tmax) Of Relugolix, E2, El, Ee, Neta",Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
348,NCT04978688,Healthy,Change From Baseline In Serum Follicle Stimulating Hormone (Fsh) At Week 6,Not Mentioned,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
349,NCT04978688,Healthy,Change From Baseline In Serum Luteinizing Hormone (Lh) At Week 6,Not Mentioned,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
350,NCT04978688,Healthy,Change From Baseline In Serum Progesterone (P) At Week 6,Not Mentioned,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
351,NCT04978688,Healthy,Change From Baseline In Serum E2 And E1 At Week 6,Not Mentioned,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
352,NCT04978688,Healthy,Change From Baseline In N-Telopeptide And C-Telopepetide Concentrations At Week 6,Not Mentioned,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
353,NCT04978688,Healthy,Incidence Of Treatment-Emergent Adverse Events,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
354,NCT04978688,Healthy,Incidence Of Hot Flush,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
355,NCT04978545,Periapical Periodontitis|Polymerase Chain Reaction|Intracanal Medicament|Enterococcus Faecalis Infection,The Sequence Analysis Of 16S Rrna Genes By The Sanger Sequencing,Not Mentioned,Not Mentioned,Change From Baseline To Postoperative 7 Days,Primary Endpoint
356,NCT04978545,Periapical Periodontitis|Polymerase Chain Reaction|Intracanal Medicament|Enterococcus Faecalis Infection,", The Quantitation Of Total Bacteria And E.Faecalis In 5 Different Samples (Sr1, S1, S2, Sr2 And S3) Taken From Teeth Were Measured Using The Ddpcr",Not Mentioned,Not Mentioned,Change From Baseline To Postoperative 7 Days,Primary Endpoint
357,NCT04978545,Periapical Periodontitis|Polymerase Chain Reaction|Intracanal Medicament|Enterococcus Faecalis Infection,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
358,NCT04978532,"Procedural Pain|Pain, Acute",Change Of Pain From Before Venipuncture To After Venipuncture (Assessed By Children),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
359,NCT04978532,"Procedural Pain|Pain, Acute",Change Of Pain From Before Venipuncture To After Venipuncture (Assessed By Parents And The Observer),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
360,NCT04978532,"Procedural Pain|Pain, Acute",Heart Rate,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
361,NCT04978532,"Procedural Pain|Pain, Acute",Oxygen Saturation,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
362,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm","Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Primary Endpoint
363,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
364,NCT04978402,Interchromosomal Breakpoint|Infertility,Estimate The It Carrier'S Reproductive Risk,Not Mentioned,Not Mentioned,Day 1,Primary Endpoint
365,NCT04978402,Interchromosomal Breakpoint|Infertility,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
366,NCT04978233,Covid-19,Change In The Acceptability Of The Opal App For Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
367,NCT04978233,Covid-19,Change In The Usability Of The Opal App For Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
368,NCT04978233,Covid-19,Contact With The Healthcare Team,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
369,NCT04978233,Covid-19,Change In Symptoms,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
370,NCT04978233,Covid-19,Patient Satisfaction With Scheduled Teleconsultations,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
371,NCT04978233,Covid-19,Change In Vital Signs Temperature,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
372,NCT04978233,Covid-19,Change In Vital Signs Respiration Rate,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
373,NCT04978233,Covid-19,Change In Vital Signs Oxygen Saturation,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
374,NCT04978233,Covid-19,Change In Vital Signs Heart Rate,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
375,NCT04978233,Covid-19,Change In Vital Signs Blood Pressure,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
376,NCT04978220,Depression Unipolar|Insomnia,Hospital Anxiety And Depression Scale (Hads),Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
377,NCT04978220,Depression Unipolar|Insomnia,Acute Stress Disorder Scale (Asds),Not Mentioned,Not Mentioned,1 Year,Secondary Endpoint
378,NCT04978155,Arterio-Venous Fistula,Functionality Of The Avf At The Time Of The Postoperative,Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
379,NCT04978155,Arterio-Venous Fistula,The Rate Of Planning Change Between The Surgical Project At The Time Of The Consultation And The Avf That Is Finally Placed,Not Mentioned,Not Mentioned,During The Surgery,Secondary Endpoint
380,NCT04978155,Arterio-Venous Fistula,"Primary, Assisted Primary And Secondary Permeability Of Our Accesses",Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
381,NCT04977921,Educational Problems,Improve Student'S Performance Per Clinical Lab Session,Not Mentioned,Not Mentioned,13 Lab Session-13 Weeks,Primary Endpoint
382,NCT04977921,Educational Problems,Evaluate Effectiveness Of Teaching Pedagogy,Not Mentioned,Not Mentioned,Week 14,Primary Endpoint
383,NCT04977921,Educational Problems,Assess Students' Perception Of Usability And Learning Of Elsevier Clinical Skill:,Not Mentioned,Not Mentioned,Up To 15 Weeks,Secondary Endpoint
384,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Reduce Labor Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
385,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Postpartum Comfort Levels,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
386,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,A Maternal Information Form,Not Mentioned,Not Mentioned,Before Birth,Primary Endpoint
387,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Visual Analog Scale For Pain (Vasp),Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
388,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Postpartum Comfort Questionnaire (Ppcq),Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
389,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Evalution Labour Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
390,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Evalution Postpartum Comfort,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
391,NCT04977713,Labor Pain|Hydrotherapy|Acupressure|Postpartum Period,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
392,NCT04977687,Machine Learning|Acute Kidney Injury|Renal Replacement Therapy|Prediction Models,Patients Required Renal Replacement Therapy,Not Mentioned,Not Mentioned,14 Days,Primary Endpoint
393,NCT04977687,Machine Learning|Acute Kidney Injury|Renal Replacement Therapy|Prediction Models,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
394,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Resolution Of Nash,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
395,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Normalization Of Hepatic Aminotransferases(Alt And Ast),Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
396,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Tumor Size,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
397,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Tumor Location,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
398,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Number Of Lesions,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
399,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Margin,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
400,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Tumor Texture,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
401,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Pancreatic Tail Contraction,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
402,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Complicated Pancreatitis,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
403,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Pancreatic Duct/Bile Duct Dilatation,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
404,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Extrapancreatic Tissue Invasion,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
405,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Hepatic Metastasis,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
406,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Lymphatic Metastasis,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
407,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Pancreas Plain Scan,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
408,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Lesion Plain Scan,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
409,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Pancreas Artery Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
410,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Lesion Artery Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
411,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Pancreas Portal Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
412,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Ct Value Of Lesion Portal Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
413,NCT04977596,"Neuroendocrine Tumor Of Pancreas|Carcinoma, Pancreatic|Ct",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
414,NCT04977557,Dry Beriberi,Change In Overall Neuropathy Limitation Scale (Onls) Score,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Primary Endpoint
415,NCT04977557,Dry Beriberi,Change In Leg Swelling,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
416,NCT04977557,Dry Beriberi,Change In Muscle Power,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
417,NCT04977557,Dry Beriberi,Change In Muscle Cramp,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
418,NCT04977557,Dry Beriberi,Change In Deep Tendon Reflexes,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
419,NCT04977557,Dry Beriberi,Change In Squat Test,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
420,NCT04977557,Dry Beriberi,Change In Pain Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
421,NCT04977557,Dry Beriberi,Change In Position Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
422,NCT04977557,Dry Beriberi,Change In Vibration Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
423,NCT04977557,Dry Beriberi,Change In Touch Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
424,NCT04977518,Infective Endocarditis,"Complications (Neurological Events, Systemic Embolism, And Congestive Heart Failure) Of Infective Endocarditis",Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
425,NCT04977518,Infective Endocarditis,Mortality,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
426,NCT04977518,Infective Endocarditis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
427,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
428,NCT04977505,Shoulder Dislocation,The Diameter Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
429,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Ossification Site,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
430,NCT04977505,Shoulder Dislocation,Unossified Area Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
431,NCT04977505,Shoulder Dislocation,Ossification Quality Score,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
432,NCT04977440,Intensive Care Unit Syndrome,Effect Of High Protein Intake On Glycemic Control,Not Mentioned,Not Mentioned,Up To 7 Days,Primary Endpoint
433,NCT04977440,Intensive Care Unit Syndrome,Effect Of High Protein Intake On Serum Electrolytes,Not Mentioned,Not Mentioned,Up To 7 Days,Primary Endpoint
434,NCT04977440,Intensive Care Unit Syndrome,Effect Of High Protein Intake On Icu Outcome,Not Mentioned,Not Mentioned,Up To 7 Days,Secondary Endpoint
435,NCT04977219,Stroke,Catherine Bergego Scale,Not Mentioned,Not Mentioned,Up To 55 Days,Primary Endpoint
436,NCT04977219,Stroke,Functional Independence Measure (Fim),Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
437,NCT04977219,Stroke,Length Of Stay,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
438,NCT04977219,Stroke,Discharge Destination,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
439,NCT04977011,"Diabetic Ketoacidosis|Heart Disease, Ischemic|Stroke|Gastrointestinal Bleeding|Acute Kidney Injury|Heart Failure|Trauma|Septic Shock|Respiratory Failure|Pneumonia|Intracerebral Hemorrhage|Head Injury|Liver Diseases",Anxiety Visual Analog Scale.,Not Mentioned,Not Mentioned,3Day,Primary Endpoint
440,NCT04977011,"Diabetic Ketoacidosis|Heart Disease, Ischemic|Stroke|Gastrointestinal Bleeding|Acute Kidney Injury|Heart Failure|Trauma|Septic Shock|Respiratory Failure|Pneumonia|Intracerebral Hemorrhage|Head Injury|Liver Diseases",Richmond Agitation Sedation Scale,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
441,NCT04977011,"Diabetic Ketoacidosis|Heart Disease, Ischemic|Stroke|Gastrointestinal Bleeding|Acute Kidney Injury|Heart Failure|Trauma|Septic Shock|Respiratory Failure|Pneumonia|Intracerebral Hemorrhage|Head Injury|Liver Diseases",Richards-Campbell Sleep Scale,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
442,NCT04976673,"Lichen Planus, Oral",Size Of Oral Lichen Planus,Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
443,NCT04976673,"Lichen Planus, Oral",Pain Rating,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
444,NCT04976543,Cirrhosis|Portal Vein Thrombosis|Esophageal Varices,Rebleeding,Not Mentioned,Not Mentioned,6-Week,Primary Endpoint
445,NCT04976543,Cirrhosis|Portal Vein Thrombosis|Esophageal Varices,Death,Not Mentioned,Not Mentioned,6-Week,Secondary Endpoint
446,NCT04976504,Desaturation Of Blood|Anesthesia,Additional Warning Time Provided By Ori Trigger,Not Mentioned,Not Mentioned,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Primary Endpoint
447,NCT04976504,Desaturation Of Blood|Anesthesia,Correlation Between Ori And Pao2,Not Mentioned,Not Mentioned,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Secondary Endpoint
448,NCT04976439,Colorectal Cancer|Apc Gene Mutation|Tp53 Gene Mutation|Pik3Ca Gene Mutation|Kras Mutation-Related Tumors|Mlh1 Gene Mutation,Description Of Clinical Characteristics,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
449,NCT04976439,Colorectal Cancer|Apc Gene Mutation|Tp53 Gene Mutation|Pik3Ca Gene Mutation|Kras Mutation-Related Tumors|Mlh1 Gene Mutation,Description Of Tumor Nature,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
450,NCT04976439,Colorectal Cancer|Apc Gene Mutation|Tp53 Gene Mutation|Pik3Ca Gene Mutation|Kras Mutation-Related Tumors|Mlh1 Gene Mutation,Description Of Survival,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
451,NCT04976439,Colorectal Cancer|Apc Gene Mutation|Tp53 Gene Mutation|Pik3Ca Gene Mutation|Kras Mutation-Related Tumors|Mlh1 Gene Mutation,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
452,NCT04976361,Prp,Measurement Of Vessel Density,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
453,NCT04976361,Prp,Measurement Of Retinal Thickness,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
454,NCT04976361,Prp,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
455,NCT04976114,Anxiety,Anxiety Level,Not Mentioned,Not Mentioned,"Presurgery, Just The Moment Before To Surgery",Primary Endpoint
456,NCT04976114,Anxiety,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
457,NCT04976088,Trauma Injury|Inflammation,"Change From Baseline In Vas Score (Visual Analogue Scale From 0 To 100 Mm, Where The Left Extreme Means ""No Pain = 0"" While The Right Extreme Means ""Worst Pain Imaginable = 100"") For Pain At Rest At 72 ± 2 Hours (Day 4) After Treatment Start.",Not Mentioned,Not Mentioned,72 Hours,Primary Endpoint
458,NCT04976088,Trauma Injury|Inflammation,Area Under The Curve (Auc) For Pain At Rest At Day 4 And Day 8 (Spid0-4D And Spid0-8D),Not Mentioned,Not Mentioned,Day 4 And Day 8,Secondary Endpoint
459,NCT04976088,Trauma Injury|Inflammation,"Change From Baseline Of Vas (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") For Pain At Rest At The Other Study Time-Points (Including Patients' Home Measurements), From Day 1 To Day 8.",Not Mentioned,Not Mentioned,"Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
460,NCT04976088,Trauma Injury|Inflammation,"Time To Resolution Of Pain At Rest, Measured Through Vas Scale (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") During From Baseline To Day 8.",Not Mentioned,Not Mentioned,From Day 1 Until The Date Of Resolution Of Pain At Rest (Maximum Day 8),Secondary Endpoint
461,NCT04976088,Trauma Injury|Inflammation,"Change From Baseline In Vas Score (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") For Pain On Movement At 72 ± 2 Hours (Day 4) And At 168 ± 2 Hours (Day 8) After Treatment Start",Not Mentioned,Not Mentioned,Day 4 And Day 8,Secondary Endpoint
462,NCT04976088,Trauma Injury|Inflammation,"Proportion Of Responder Patients (Defined As A Decrease ≥ 50% Of Baseline Vas (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") For Pain At Rest And On Movement) At 72 ± 2 Hours (Day 4) After Treatment Start",Not Mentioned,Not Mentioned,Day 4,Secondary Endpoint
463,NCT04976088,Trauma Injury|Inflammation,Proportion Of Patients That Used Rescue Medication (Paracetamol) From Baseline To Day 8 Usign A Patient Diary,Not Mentioned,Not Mentioned,From Baseline To Day 8,Secondary Endpoint
464,NCT04976088,Trauma Injury|Inflammation,"Amount Of Tablets Of Rescue Medication Consumed From Baseline To Day 8, Using A Patient Diary",Not Mentioned,Not Mentioned,From Baseline To Day 8,Secondary Endpoint
465,NCT04976088,Trauma Injury|Inflammation,"Imp Adhesion, Performed Daily By Patients And At Day 4 And Day 8 By The Open Staff Member; Following 5-Point Ordinal Scale: 0:≥90% Adhered; 1:≥75% To <90% Adhered; 2:≥50% To <75% Adhered; 3:<50% Adhered But Not Detached; 4:Plaster Detached",Not Mentioned,Not Mentioned,"Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
466,NCT04976088,Trauma Injury|Inflammation,"Safety As Change From Baseline To Day 8 Evaluated By Physical Examination Using Observation, Palpitation, Percussion, And Auscultation",Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
467,NCT04976088,Trauma Injury|Inflammation,Safety As Change From Baseline To Day 8 Evaluated By Systolic Blood Pressure Measured In Mmhg,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
468,NCT04976088,Trauma Injury|Inflammation,Safety As Change From Baseline To Day 8 Evaluated By Diastolic Blood Pressure Measured In Mmhg,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
469,NCT04976088,Trauma Injury|Inflammation,Safety As Change From Baseline To Day 8 Evaluated By Heart Rate Measured In Bpm,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
470,NCT04976088,Trauma Injury|Inflammation,Safety As Change From Baseline To Day 8 Evaluated By Tracking The Number Of Patient Withdrawals,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
471,NCT04976088,Trauma Injury|Inflammation,Safety As Change From Baseline To Day 8 Evaluated By Tracking The Number Of Adverse Events,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
472,NCT04976088,Trauma Injury|Inflammation,"Local Tolerability (Erythema) At The Imp Application Site By Investigator At Day 1, Day 4 And Day 8 Based On A 8-Point Categorical Scale, Where 0=No Evidence Of Irritation And 7=Strong Reaction Spreading Beyond Test Site",Not Mentioned,Not Mentioned,"Day 1, Day 4 And Day 8",Secondary Endpoint
473,NCT04976088,Trauma Injury|Inflammation,"Local Tolerability (Itching) At The Imp Application Site By Investigator At Day 1, Day 4 And Day 8 Based On A 4-Point Categorical Scale, Where 0=Absent And 3=Severe",Not Mentioned,Not Mentioned,"Day 1, Day 4 And Day 8",Secondary Endpoint
474,NCT04976088,Trauma Injury|Inflammation,"Local Tolerability (Burning) At The Imp Application Site By Investigator At Day 1, Day 4 And Day 8 Based On A 4-Point Categorical Scale, Where 0=Absent And 3=Severe",Not Mentioned,Not Mentioned,"Day 1, Day 4 And Day 8",Secondary Endpoint
475,NCT04976088,Trauma Injury|Inflammation,"Local Tolerability (Local Pain) At The Imp Application Site By Investigator At Day 1, Day 4 And Day 8 Based On A 4-Point Categorical Scale, Where 0=Absent And 3=Severe",Not Mentioned,Not Mentioned,"Day 1, Day 4 And Day 8",Secondary Endpoint
476,NCT04976088,Trauma Injury|Inflammation,"Global Assessment Of Local Tolerability At Imp Administration Site By Investigator And Patient According To The Following Score: 3=Excellent; 2=Good; 1=Fair; 0=Poor, Assessed At Day 4 And Day 8.",Not Mentioned,Not Mentioned,Day 4 And Day 8,Secondary Endpoint
477,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Mean Change In Pain Score,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
478,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Mean Change In Inflammation (Cell And Flare) Scores,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
479,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Resolution Of Pain,Not Mentioned,Not Mentioned,Assessed For 1 Months After Drug Insertion,Secondary Endpoint
480,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Resolution Of Anterior Chamber Inflammation,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
481,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Proportion Of Eyes Requiring Additional Post-Operative Therapy,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
482,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Number Of Patient Call-Backs Regarding Post-Operative Pain,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
483,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Number Of Pharmacy Call-Backs Regarding Post-Operative Medication,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
484,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Adverse Events,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
485,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Mean Change In Iop,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
486,NCT04975971,Anterior Chamber Inflammation|Ocular Pain|Corneal Edema|Corneal Defect|Penetrating Keratoplasty|Nuclear Cataract|Cortical Cataract|Cataract Senile,Change In Bcva,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
487,NCT04975659,Communication,Pain Score,Not Mentioned,Not Mentioned,"Throughout Study Completion, Average Of 10 Months",Primary Endpoint
488,NCT04975659,Communication,Baseline Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
489,NCT04975659,Communication,Preoperative Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
490,NCT04975659,Communication,Association Of Education Level On Pain And Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
491,NCT04975659,Communication,Association Of Past History Of Regional Anesthesia On Pain And Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
492,NCT04975542,Respiratory Function Impaired,Change In Chest Wall Excursion,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Chest Wall Excursion Within 5 Minutes Of Treatment Completion.,Primary Endpoint
493,NCT04975542,Respiratory Function Impaired,Change In Forced Vital Capacity (Fvc),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fvc Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
494,NCT04975542,Respiratory Function Impaired,Change In Forced Expiratory Volume At 1 Second (Fev1),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline In Forced Expiratory Volume At 1 Second Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
495,NCT04975542,Respiratory Function Impaired,Change In Fev1/Fvc Ratio,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fev1/Fvc Ratio Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
496,NCT04975542,Respiratory Function Impaired,Change In Respiratory Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Respiratory Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
497,NCT04975542,Respiratory Function Impaired,Change In Heart Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Heart Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
498,NCT04975542,Respiratory Function Impaired,Oxygen Saturation (Spo2),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Oxygen Saturation Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
499,NCT04975529,Exercise|Diet,Mean Change From Baseline In Youth Self-Reported Physical Activity Using The Patient-Reported Outcomes Measurement Information System (Promis) Measure At 6-Months,Not Mentioned,Not Mentioned,Change From Baseline To End Of The 6-Month Intervention,Primary Endpoint
500,NCT04975529,Exercise|Diet,Mean Change From Baseline In Youth Self-Reported Self-Efficacy For Physical Activity Using The Validated Physical Activity Self-Efficacy Scale At 6-Months,Not Mentioned,Not Mentioned,Change From Baseline To End Of The 6-Month Intervention,Secondary Endpoint
501,NCT04975529,Exercise|Diet,Mean Change From Baseline In Youth Self-Reported Dietary Intake Assessed Using The National Cancer Institute (Nci) Fruit And Vegetable Screener At 6-Months,Not Mentioned,Not Mentioned,Change From Baseline To End Of The 6-Month Intervention,Secondary Endpoint
502,NCT04975529,Exercise|Diet,Mean Change From Baseline In Youth Self-Confidence Assessed Using The Positive Youth Development (Pyd) Short Form Confidence Scale At 6-Months,Not Mentioned,Not Mentioned,Change From Baseline To End Of The 6-Month Intervention,Secondary Endpoint
503,NCT04975412,Acne Vulgaris,Acne Severity,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
504,NCT04975412,Acne Vulgaris,Whole Blood Zinc Level,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
505,NCT04975412,Acne Vulgaris,Demographics,Not Mentioned,Not Mentioned,Initial Consult,Secondary Endpoint
506,NCT04975360,Sleep Inertia|Caffeine|Placebo,Acute Sleep Inertia Questionnaire,Not Mentioned,Not Mentioned,At 07:00 Hours After Caffeine And Placebo Administration,Primary Endpoint
507,NCT04975360,Sleep Inertia|Caffeine|Placebo,Polysomnographic Recording Of Nocturnal Sleep,Not Mentioned,Not Mentioned,Between 03:00-07:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
508,NCT04975360,Sleep Inertia|Caffeine|Placebo,Caffeine Effects Questionnaire,Not Mentioned,Not Mentioned,Between 07:15-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
509,NCT04975360,Sleep Inertia|Caffeine|Placebo,Positive And Negative Affect Schedule,Not Mentioned,Not Mentioned,Between 07:00-08:15 Hours After Caffeine And Placebo Administration,Secondary Endpoint
510,NCT04975360,Sleep Inertia|Caffeine|Placebo,Psychomotor Vigilance Task,Not Mentioned,Not Mentioned,Between 07:15-07:30 Hours After Caffeine And Placebo Administration,Secondary Endpoint
511,NCT04975360,Sleep Inertia|Caffeine|Placebo,N-Back Task,Not Mentioned,Not Mentioned,Between 07:30-07:40 Hours After Caffeine And Placebo Administration,Secondary Endpoint
512,NCT04975360,Sleep Inertia|Caffeine|Placebo,D2 Attention Task,Not Mentioned,Not Mentioned,Between 07:40-07:45 Hours After Caffeine And Placebo Administration,Secondary Endpoint
513,NCT04975360,Sleep Inertia|Caffeine|Placebo,Cortisol Awakening Response,Not Mentioned,Not Mentioned,Between 07:00-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
514,NCT04975360,Sleep Inertia|Caffeine|Placebo,Polysomnographic Recording Of Morning Nap Opportunity,Not Mentioned,Not Mentioned,Between 08:00-09:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
515,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Fitting,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
516,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Positioning,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
517,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Proximal Contact,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
518,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Marginal Adaptation,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
519,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)","Color: Match, Staining/Color Change",Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
520,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Gingival Status,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
521,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Retention Of The Crown,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
522,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Integrity Of The Veneer/Composite,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
523,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Secondary Caries,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
524,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",History Of Trauma,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
525,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Clinical Pulp Pathology,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
526,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Radiographical Pulp Pathology,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
527,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Parent'S Esthetic Satisfaction,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
528,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
529,NCT04975282,"Preterm|Feeding, Bottle|Feeding Behavior|Feeding, Breast",Transition To Full Breastfeeding,Not Mentioned,Not Mentioned,"From Transition To Breastfeeding, Up To 1 Week.",Primary Endpoint
530,NCT04975282,"Preterm|Feeding, Bottle|Feeding Behavior|Feeding, Breast",Discharge Time,Not Mentioned,Not Mentioned,"From Admission To Discharge, Up To 4 Weeks",Primary Endpoint
531,NCT04975282,"Preterm|Feeding, Bottle|Feeding Behavior|Feeding, Breast",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
532,NCT04975126,Cataract,Decisional Conflict Scale Score,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
533,NCT04975126,Cataract,Decision Regret Scale Score,Not Mentioned,Not Mentioned,1 Month After Surgery,Primary Endpoint
534,NCT04975126,Cataract,Number Of Correctly Answered Questions Assessing Knowledge,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
535,NCT04975126,Cataract,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
536,NCT04975113,Patellofemoral Pain Syndrome|Kinesiotape|Exercise|Strength,Change From Visual Analogue Pain Scale Score At 6Th. Weeks And 12Th. Weeks,Not Mentioned,Not Mentioned,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
537,NCT04975113,Patellofemoral Pain Syndrome|Kinesiotape|Exercise|Strength,Change From Isokinetic Muscle Strength Of The Hamstring And Quadriceps Femoris Muscles At 6Th. Weeks And 12Th. Weeks,Not Mentioned,Not Mentioned,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
538,NCT04975113,Patellofemoral Pain Syndrome|Kinesiotape|Exercise|Strength,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
539,NCT04975048,Healthy|Gen1 Gene Mutation,Changes In Serum Lipids,Not Mentioned,Not Mentioned,"Week 0, Week 4, Week 8, Week 16",Primary Endpoint
540,NCT04975048,Healthy|Gen1 Gene Mutation,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
541,NCT04975022,"Pk, Pd, And Safety",Cmax,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
542,NCT04975022,"Pk, Pd, And Safety",Auc 0-8 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
543,NCT04975022,"Pk, Pd, And Safety","Aucgir,0-8 H",Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
544,NCT04975022,"Pk, Pd, And Safety",Girmax,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
545,NCT04975022,"Pk, Pd, And Safety",Tmax,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 Minutes；",Secondary Endpoint
546,NCT04975022,"Pk, Pd, And Safety",Auc 0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120 Minutes",Secondary Endpoint
547,NCT04975022,"Pk, Pd, And Safety",The Elimination Half-Life (T1/2) Of Serum Insulin,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
548,NCT04975022,"Pk, Pd, And Safety",The Auc For Insulin From Time Zero To 4 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240 Minutes",Secondary Endpoint
549,NCT04975022,"Pk, Pd, And Safety",The Auc For Insulin From Time Zero To Infinite Time,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
550,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-2 Hours",Secondary Endpoint
551,NCT04975022,"Pk, Pd, And Safety",Aucgir，0-4 H,Not Mentioned,Not Mentioned,"Pre-Dose, 0-4 Hours",Secondary Endpoint
552,NCT04975022,"Pk, Pd, And Safety",Tgirmax,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Secondary Endpoint
553,NCT04974983,Glioblastoma|Angiogenesis,Functional Outcome,Not Mentioned,Not Mentioned,15 Months,Primary Endpoint
554,NCT04974983,Glioblastoma|Angiogenesis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
